TABLE 2.
Outcome | Contraceptive method | |||||
---|---|---|---|---|---|---|
Hormonal | IUD | |||||
n/N | Patient-years of follow-up | Rate/100 patient-years (95% CI) | n/N | Patient-years of follow-up | Rate/100 patient-years (95% CI) | |
Pregnancy | 27/303 | 585 | 4.62 (3.17–6.73) | 14/296 | 645 | 2.17 (1.29–3.67) |
Discontinuation of randomized method | 38/303 | 558 | 6.81 (4.95–9.35) | 146/296 | 510 | 28.6 (24.4–33.7) |
Pelvic inflammatory disease | 0/303 | 588 | 0.00 (0.00–0.51)* | 1/296 | 642 | 0.16 (0.004–87)* |
Death | 17/303 | 588 | 2.89 (1.80–4.65) | 13/296 | 645 | 2.01 (1.17–3.47) |
CD4 count falling to <200 cells/μL† | 56/273 | 499 | 11.2 (8.64–14.6) | 41/265 | 548 | 7.48 (5.51–10.2) |
CD4 count falling to <200 cells/μL or death | 72/303 | 547 | 13.2 (10.5–16.6) | 52/296 | 607 | 8.57 (6.53–11.2) |
Because of sparse numbers of events, CIs were calculated using exact methods based on Poisson count.
Restricted to women with baseline CD4+ count of >200 cell/μL (n = 538).